<- Go Home
OncoZenge AB (publ)
OncoZenge AB (publ), is a clinical-stage pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. The company offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity. The company was founded in 2020 and is headquartered in Bromma, Sweden.
Market Cap
SEK 92.3M
Volume
44.0K
Cash and Equivalents
SEK 935.0K
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
SEK 71.0K
Profit Margin
100.00%
52 Week High
SEK 10.28
52 Week Low
SEK 4.51
Dividend
N/A
Price / Book Value
257.82
Price / Earnings
-3.56
Price / Tangible Book Value
-14.22
Enterprise Value
SEK 98.9M
Enterprise Value / EBITDA
N/A
Operating Income
-SEK 22.6M
Return on Equity
446.60%
Return on Assets
-120.16
Cash and Short Term Investments
SEK 935.0K
Debt
SEK 7.5M
Equity
SEK 358.0K
Revenue
SEK 71.0K
Unlevered FCF
-SEK 12.4M
Sector
Pharmaceuticals
Category
N/A